Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right ...
Hims & Hers Health, Inc. (HIMS) closed at $28.89 in the latest trading session, marking a -5.19% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 1.16% for the ...
Hims & Hers Health, Inc. faces short-term pressure after missing Novo’s partner list, but lab testing boosts long-term growth ...
Hims & Hers stock has nosedived in the past few months. It has dived by over 56% from its highest point in July last year and ...
Hims & Hers is down 30% but still a Buy: margin expansion, GLP-1 clarity, new hormone care, and global growth. Learn more about HIMS stock here.
Zacks Investment Research on MSN
Hims & Hers expands platform-led access to digital healthcare
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, built its growth strategy around a highly scalable, ...
Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.
The research, conducted by Talker Research on behalf of Hims, Inc., shows those expenses stretch across everyday life, from ...
During 2025, Hims & Hers further deepened this foundation through targeted investments in data and AI. Leadership additions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback